

Fig. 1/6

Matrix with rotigotine particles after dispersion without solvents and/or emulsifier




Fig. 2/6

Matrix according to the invention with amorphous rotigotine particles




Fig. 3/6

Comparison of the in vitro penetration rates through mouse skin from the transdermal systems (Charge 20204071) according to the invention and from the comparison examples 2a (20107012) and 2b (20204074), i.e., with and without additives acting as solubility and/or dispersion agents.




Fig. 4/6

Comparison of the in vitro penetration rates through human skin from the transdermal systems according to the invention after 5 months storage (Charge 20204071) and from the TTSs (WE11682) known from WO 99/49852.





Fig. 5/6



Example of a schematic structure of a monolithic TTS

Fig. 6/6

Comparison of the in vitro penetration rates through mouse skin from the transdermal systems according to the invention (Charge 20204071, tempered) and from the comparison examples 2a (20107012) and 3 (Charge 20204071, non-tempered) after 12 months storage.

